What happened
On July 27, a new nonprofit called the Pharmacy Compounding Accreditation Council incorporated in Delaware as a 501(c)(3) and announced it will operate publicly as the Peptide Council. Its mission is to build the first accreditation standards written specifically for peptide compounding, covering the chain from the raw ingredient supplier through the compounding pharmacy to the telehealth company that writes the prescription. The organization has seated an interim board and is now hiring a founding CEO. No standard exists yet, and no pharmacy has been accredited. This is the announcement of an intent to build one, not a working program.
The proposed standards, which the Council calls "Powder to Patient," would cover qualifying ingredient suppliers, standardized certificates of analysis from accredited testing labs, uniform labeling and dosing information, adverse event tracking, and limits on marketing claims that overstate what a compounded peptide can do. A separate piece would set accreditation criteria for the telehealth companies that prescribe these compounds.
Two different groups share a similar name
This is worth being careful with. The FDA's Pharmacy Compounding Advisory Committee, the body that voted in July to recommend six of the seven peptides under review for the compounding Bulks List, is a government advisory panel. The new Peptide Council's formal name, the Pharmacy Compounding Accreditation Council, produces the same acronym, PCAC, but it's an unrelated private nonprofit with no regulatory authority. One votes on what pharmacies are allowed to compound. The other wants to certify, on a voluntary basis, that a pharmacy is doing that work well. Neither one is the FDA, and neither one has approved or accredited anything on its own yet.
The timing isn't a coincidence. The Council launched days after that FDA advisory panel voted, over the objections of the FDA's own staff scientists, to recommend expanding the peptides pharmacies can legally compound. If that recommendation moves forward, more peptides become eligible for compounding and more compounding pharmacies enter the market. The Council's founders are betting that market needs a quality check that doesn't exist yet, in a lane the FDA's Bulks List vote doesn't touch.
Why the Council says the gap is real
"Most compounding issues are not caused by the quality compounders doing the work right, it was caused by bad actors operating without meaningful oversight and by a regulatory environment that has no mechanism to tell the difference," said Lee Rosebush, chair of the Peptide Council's interim board, in a statement reported by the American Journal of Managed Care. Rosebush also chairs the American Academy of Peptide Medicine and the Outsourcing Facilities Association.
Existing oversight doesn't disappear here. State pharmacy boards, the FDA's 503A and 503B compounding framework, and general accreditors like the Accreditation Commission for Health Care already cover more than 900 compounding pharmacies. The Council wants to add peptide-specific criteria on top of that general layer, working with existing accreditors as inspection partners rather than building a competing inspection system. To limit conflicts of interest, it says most of its permanent board will hold no financial stake in compounding pharmacy operations, and that it will be funded through accreditation fees rather than donations.
The checklist you can use today
Shawn Hodges, a pharmacist who leads a national network of compounding pharmacies, gave the American Journal of Managed Care a plain answer to the obvious question, what do you do until Council accreditation exists. His advice has three parts. Look for a pharmacy registered with the FDA as a 503B outsourcing facility, which he called the highest current regulatory bar, or one that's a 503A compounder already accredited by an existing body such as ACHC. Ask the pharmacy directly for certificates of analysis on its ingredients. And ask it to document how it qualifies its suppliers in the first place, not just whether it tests the finished product.
What this means for you right now
If you buy peptides sold for research use, this council doesn't reach you directly. Its accreditation targets licensed compounding pharmacies, ingredient suppliers, and telehealth companies that write prescriptions, a different lane than a research-use vendor shipping a vial to your door. What it signals is broader. A group with real industry standing has concluded the peptide compounding market has outgrown the oversight it was built with, the same gap that shapes most of what we cover here. Whichever lane you're buying in, the same habit protects you either way, compare a real price and a real certificate of analysis before you trust either one. That's what our price comparison tool and the vendor directory are built for.
If you're getting a compounded peptide through a prescription or a telehealth service right now, use Hodges's checklist as your working standard until the Council's own accreditation exists. Ask for the pharmacy's FDA registration status, ask for certificates of analysis, and ask how it qualifies its ingredient suppliers. A pharmacy that answers all three clearly is doing more than the bare legal minimum requires.
What to watch next is whether the Council hires its founding CEO and finalizes its standards, and whether the FDA accepts its advisory committee's recommendation to expand the Bulks List, since that decision will shape how much of the market the Council's standards eventually need to cover. We'll follow both here.
Sources
- 1. Steinzor, Pearl. "New Nonprofit Launches to Develop Peptide Compounding Quality Standards." The American Journal of Managed Care, August 5, 2026.
- 2. Gilbert, Daniel, Yamaguchi, Adam, and Geller, Laura. "Judge sentences peptide vendor to nearly 6 years in prison for 'an incredible trail of harm.'" CBS News, July 30, 2026.